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Abstract
Tibia fracture in rats followed by cast immobilization leads to nociceptive, trophic, vascular and bone-related
changes similar to those seen in Complex Regional Pain Syndrome (CRPS). Substance P (SP) mediated neurogenic
inflammation may be responsible for some of the signs of CRPS in humans. We therefore hypothesized that SP
acting through the SP receptor (NK1) leads to the CRPS-like changes found in the rat model. In the present study,
we intradermally injected rats with SP and monitored hindpaw mechanical allodynia, temperature, and thickness as
well as tissue levels of tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), and nerve growth
factor-β (NGF) for 72 h. Anti-NGF antibody was utilized to block the effects of SP-induced NGF up-regulation.
Fracture rats treated with the selective NK1 receptor antagonist LY303870 prior to cast removal were assessed for
BrdU, a DNA synthesis marker, incorporation in skin cells to examine cellular proliferation. Bone microarchitecture
was measured using micro computed tomography (μCT). We observed that: (1) SP intraplantar injection induced
mechanical allodynia, warmth and edema as well as the expression of nociceptive mediators in the hindpaw skin
of normal rats, (2) LY303870 administered intraperitoneally after fracture attenuated allodynia, hindpaw unweighting,
warmth, and edema, as well as cytokine and NGF expression, (3) LY303870 blocked fracture-induced epidermal
thickening and BrdU incorporation after fracture, (4) anti-NGF antibody blocked SP-induced allodynia but not
warmth or edema, and (5) LY303870 had no effect on bone microarchitecture. Collectively our data indicate that
SP acting through NK1 receptors supports the nociceptive and vascular components of CRPS, but not the
bone-related changes.
Introduction
Complex regional pain syndrome (CRPS) is a painful,
disabling and often chronic condition affecting the ex-
tremities and is a frequent sequela of tibial and radial
fractures [1]. Previously we described a distal tibial frac-
ture model in rats that exhibits chronic unilateral hind-
limb warmth, edema, facilitated spontaneous protein
extravasation, allodynia, postural unweighting, and peri-
articular osteoporosis [2]. These post-fracture changes
closely resemble the clinical presentation of patients
with acute CRPS.
The inflamed appearance of the limb affected by CRPS
has led to the hypothesis that the local production of in-
flammatory mediators might be involved in the etiology
of the condition. There is increased TNF-α and IL-6 in
blister fluid from patients with early CRPS [3]. Similarly,
we have observed a dramatic increase in hindpaw skin
expression of TNF-α, IL-1β, IL-6, and nerve growth fac-
tor (NGF) at both the mRNA and protein levels [4-6] in
the rat fracture model. Treating fractured rats with a
TNF-α inhibitor (etanercept), an IL-1 receptor antagon-
ist (anakinra), or an anti-NGF antibody (tanezumab)
reduced hindpaw allodynia and unweighting at 4 weeks
post-fracture [4,5,7]. These data indicate that fracture-
induced allodynia can be attributed partially to local in-
flammatory mediators because all these drugs are large
molecular weight proteins that cannot cross the blood
brain barrier. Recently we identified keratinocytes in the
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fracture-affected dorsal hindpaw as the primary cellu-
lar source of the inflammatory nociceptive mediators
TNF-α, IL-1β, IL-6, and NGF in the rat fracture CRPS
model [8].
Several lines of clinical investigation support the hy-
pothesis that facilitated peripheral neurogenic inflamma-
tion, involving neuropeptides such as substance P (SP),
contributes to some of the signs and symptoms of CRPS
[9-12]. When SP is microdialyzed in the skin of normal
volunteers and patients with CRPS, much greater
protein extravasation is observed in CRPS-affected
limbs, indicating post-junctional facilitation of the SP ex-
travasation response [11,13]. Furthermore, tibial fracture
in rats upregulates NK1 receptor expression in skin
(keratinocytes) and microvasculature (endothelial cells)
of the affected hindpaw [14], and SP signaling is
enhanced in the injured limb of these animals [2,14,15].
Treatment with the selective NK1 antagonist LY303870
attenuated spontaneous protein extravasation, edema,
warmth, and allodynia in the hindpaw after fracture [2].
SP can induce keratinocyte proliferation and activation
in vitro [16,17], and in rats electrical stimulation of the
sciatic nerve at intensities causing neuropeptide release
leads to a gradual increase in hindpaw skin levels of
TNF-α, IL-1β, IL-6, and NGF [18]. When SP or calci-
tonin gene-related peptide (CGRP) was microdialyzed in
the skin of normal volunteers there was no immediate
pain response [13]. These data support the premise that
SP and CGRP act as intermediate mediators in the de-
velopment of inflammatory pain via other downstream
substances such as cytokines and NGF.
In light of these observations, we hypothesized that: 1)
exogenous SP signaling in the skin can sequentially up-
regulate the expression of TNF-α, IL-1β, IL-6, and NGF,
resulting in hindpaw nociceptor sensitization, allodynia
and unweighting; 2) NGF is the final downstream in-
flammatory mediator for SP-induced cutaneous noci-
ceptive sensitization; 3) endogenous SP signaling in the
fractured limb activates keratinocytes and upregulates
expression of TNF-α, IL-1β, IL-6, and NGF, resulting in
hindpaw nociceptor sensitization, allodynia and un-
weighting, and 4) SP signaling after fracture induces
periarticular bone loss. The experiments described in
this study were designed to test these hypotheses.
Materials and methods
These experiments were approved by our institute’s
Subcommittee on Animal Studies and followed the
guidelines of the International Association for the
Study of Pain (IASP) [19]. Adult (9-month-old) male
Sprague Dawley rats (Simonsen Laboratories, Gilroy,
CA, USA) were used in all experiments. The animals
were housed individually in isolator cages with solid
floors covered with 3 cm of soft bedding and were fed
and watered ad libitum. During the experimental
period the animals were fed Lab Diet 5012 (PMI Nutri-
tion Institute, Richmond, IN, USA), which contained
1.0% calcium, 0.5% phosphorus, and 3.3 IU/g of vitamin
D3, and were kept under standard conditions with a
12-h light–dark cycle.
Surgery
Tibial fracture was performed under isoflurane anes-
thesia as we have previously described [2]. The right
hindlimb was wrapped in stockinet (2.5 cm wide) and
the distal tibia was fractured using pliers with an adjust-
able stop that had been modified with a 3-point jaw. The
hindlimb was wrapped in casting tape so the hip, knee
and ankle were flexed. The cast extended from the meta-
tarsals of the hindpaw up to a spica formed around the
abdomen. To prevent the animals from chewing at their
casts, the cast material was wrapped in galvanized wire
mesh. The rats were given subcutaneous saline and
buprenorphine (0.03 mg/kg) immediately after the pro-
cedure and on the next day after fracture for postopera-
tive hydration and analgesia. At 4 weeks the rats were
anesthetized with isoflurane and the cast removed with a
vibrating cast saw. All rats used in this study had union
at the fracture site after 4 weeks of casting.
Drugs
The anti-NGF antibody muMab 911 (Rinat Laboratories,
Pfizer Inc, SF, CA, USA) is a TrkA immunoglobulin G
(TrkA-IGG) fusion molecule that binds to the NGF mol-
ecule, thus blocking the binding of NGF to the TrkA
and p75 NGF receptors and inhibiting TrkA autopho-
sphorylation [20]. Pharmacokinetic and behavioral ex-
periments in rodents indicate that muMab 911 has a
terminal half-life of 5 to 6 days in plasma and that a
10 mg/kg dose administered every 5 or 6 days reduces
nociceptive behavior in a variety of rodent chronic pain
models [21-23].
The NK1 receptor antagonist LY303870 was a gener-
ous gift from Dr. L. Phebus (Eli Lily Company, Indian-
apolis, IN, USA). This compound has nanomolar affinity
for the rat NK1 receptor, has no affinity for 65 other
receptors and ion channels, has no sedative, cardiovas-
cular or core body temperature effects in rats at systemic
doses up to 30 mg/kg, and is physiologically active for
24 h after a single systemic dose of 10 mg/kg [24-26].
Hindpaw nociception
To measure mechanical allodynia in the rats an up-
down von Frey testing paradigm was used as we have
previously described [2,15,27]. Rats were placed in a
clear plastic cylinder (20 cm in diameter) with a wire
mesh bottom and allowed to acclimate for 15 minutes.
The paw was tested with one of a series of eight von
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Frey hairs ranging in stiffness from 0.41 g to 15.14 g.
The von Frey hair was applied against the hindpaw plan-
tar skin at approximately midsole, taking care to avoid
the tori pads. The fiber was pushed until it slightly
bowed and then it was jiggled in that position for 6 sec-
onds. Stimuli were presented at an interval of several
seconds. Hindpaw withdrawal from the fiber was consid-
ered a positive response. The initial fiber presentation
was 2.1 g and the fibers were presented according to the
up-down method of Dixon to generate six responses in
the immediate vicinity of the 50% threshold. Stimuli
were presented at an interval of several seconds. An
incapacitance device (IITC Inc. Life Science, Woodland,
CA, USA) was used to measure hindpaw unweighting.
The rats were manually held in a vertical position over
the apparatus with the hindpaws resting on separate
metal scale plates and the entire weight of the rat was
supported on the hindpaws. The duration of each meas-
urement was 6 s and 10 consecutive measurements were
taken at 60-second intervals. Eight readings (excluding
the highest and lowest ones) were averaged to calculate
the bilateral hindpaw weight-bearing values.
Hindpaw temperature
The room temperature was maintained at 23°C and hu-
midity ranged between 25 and 45%. The temperature of
the hindpaw was measured using a fine wire thermo-
couple (Omega, Stanford, CT, USA) applied to the paw
skin, as previously described [2,15,27]. The investigator
held the thermistor wire using an insulating Styrofoam
block. Three sites were tested over the dorsum of the
hindpaw; the space between the first and second
metatarsals (medial), the second and third metatarsals
(central), and the fourth and fifth metatarsals (lateral).
After a site was tested in one hindpaw the same site was
immediately tested in the contralateral hindpaw. The
testing protocol was medial dorsum right then left, cen-
tral dorsum right then left, lateral dorsum right then left,
medial dorsum left then right, central dorsum left then
right, and lateral dorsum left then right. The six mea-
surements for each hindpaw were averaged for the mean
temperature.
Hindpaw thickness
A laser sensor technique was used to determine the
dorsal-ventral thickness of the hindpaw, as we have pre-
viously described [15]. Before baseline testing the bilat-
eral hindpaws were tattooed with a 2 to 3 mm spot on
the dorsal skin over the midpoint of the third metatarsal.
For laser measurements each rat was briefly anesthetized
with isoflurane and then held vertically so the hindpaw
rested on a table top below the laser. The paw was gen-
tly held flat on the table with a small metal rod applied
to the top of the ankle joint. Using optical triangulation,
a laser with a distance measuring sensor was used to de-
termine the distance to the table top and to the top of
the hindpaw at the tattoo site and the difference was
used to calculate the dorsal-ventral paw thickness. The
measurement sensor device used in these experiments
(4381 Precicura, Limab, Goteborg, Sweden) has a meas-
urement range of 200 mm with a 0.01 mm resolution.
Homogenization procedure and enzyme immunoassay for
TNF-α, IL-1β, IL-6 and NGF
Rat hindpaw dorsal skin was collected after behavioral
testing or at time points as indicated and frozen imme-
diately on dry ice. Skin tissue was cut into fine pieces in
ice-cold phosphate buffered saline (PBS), pH 7.4,
containing protease inhibitors (aprotinin (2 μg/ml),
leupeptin (5 μg/ml), pepstatin (0.7 μg/ml), and PMSF
(100 μg/ml); Sigma, St. Louis, MO, USA) followed by
homogenization using a rotor/stator homogenizer. Ho-
mogenates were centrifuged for 5 minutes at 14,000 g,
and at 4°C. Supernatants were transferred to fresh pre-
cooled Eppendorf tubes. Triton X-100 (Boehringer
Mannheim, Germany) was added at a final concentration
0.01%. The samples were centrifuged again for 5 minutes
at 14,000 g at 4°C. The supernatants were aliquoted and
stored at −80°C. TNF-α, IL-1β, and IL-6 protein levels
were determined using EIA kits (R&D Systems, Minne-
apolis, MN, USA). The NGF concentrations were deter-
mined using the NGF EmaxW ImmunoAssay System kit
(Promega, Madison, WI, USA) according to the manu-
facturer’s instructions. The optical density (OD) of the
reaction product was read on a microplate reader at
450 nm. The concentrations of TNF-α, IL-1β, IL-6, and
NGF proteins were calculated from the standard curve
at each assay. Positive and negative controls were in-
cluded in each assay. Each protein concentration was
expressed as pg/mg total protein. Total protein contents
in all tissue extracts were measured by the Coomassie
Blue Protein Assay Kit (Pierce, Rockford, IL, USA).
Tissue processing and keratinocyte immunofluorescence
confocal microscopy
Animals were euthanized and immediately perfused with
4% paraformaldehyde (PFA) in PBS, pH 7.4, via the
ascending aorta; the hindpaw skin including sub-dermal
layers was removed and post-fixed in 4% PFA for 2 h,
and then the tissues were treated with 30% sucrose in
PBS at 4°C before embedding in the optimal cutting
temperature compound (OCT) (Sakura Finetek USA, Inc.,
Torrance, California, USA). Following embedding, 10-μm
thick slices were made using a cryostat, mounted onto
Superfrost microscope slides (Fisher Scientific, Pitts-
burgh, PA, USA), and stored at −80°C.
To examine the effects of intraplantar SP on inflamma-
tory mediator production and NK1 receptor expression
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in epidermal keratinocytes, double immunolabeling was
performed as previously described [8]. Briefly, frozen skin
sections were permeabilized and blocked with PBS con-
taining 10% donkey serum and 0.3% Triton X-100,
followed by exposure to the primary antibodies overnight
at 4°C in PBS containing 2% serum. Upon detection of
the first antigen, a primary antibody from a different
species against the second antigen was applied to the
sections and visualized using an alternative fluorophore-
conjugated secondary antibody. Sections were then
rinsed in PBS and incubated with fluorophore-
conjugated secondary antibodies against the immuno-
globulin of the species from which the primary antibody
was generated. After three washes, the sections were
mounted with anti-fade mounting medium (Invitrogen,
Grand Island, NY, USA). With regard to primary anti-
bodies, goat anti-rat IL-1β (R&D Systems, 1:200), goat
anti-rat NGF-β (R&D Systems, 1:100), rabbit anti-rat
NK1 receptor (Sigma-Aldrich, diluted 1:8000) and mono-
clonal mouse anti-rat keratin (clone AE1/AE3) (Thermo
Fisher Scientific, Waltham, MA 02454, USA, diluted
1:50) were used. Double-labeling immunofluorescence
was performed with a series of conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories), that
is, donkey anti-mouse IgG (1:500) conjugated with fluor-
escein isothiocyanate (FITC) and donkey anti-goat IgG
(1:500) conjugated with cyanine dye 3 (Cy3) for co-
immunostaining of keratin and IL-1β or NGF, and don-
key anti-mouse IgG (1:500) conjugated with Cy3 and
donkey anti-rabbit IgG (1:500) conjugated with FITC for
co-staining of keratin and NK1 receptor, respectively.
To assess LY303870 effects on epidermal thickness
at 4 weeks post-fracture, the sections of hindpaw skin
were permeabilized and blocked as described above, fol-
lowed by exposure to monoclonal anti-rat keratin
(clone AE1/AE3) (Thermo Fisher Scientific, diluted 1:50)
overnight at 4°C in PBS containing 2% serum. The pri-
mary antibody was detected using FITC-conjugated
donkey anti-mouse IgG (H+C) antibody (Jackson Immu-
no Reasearch Laboratories, West Grove, PA, USA, diluted
1:500). Images were obtained using confocal microscopy
(Zeiss LSM/510 Upright 2 photon; Carl Zeiss, Thornwood,
NY, USA) and stored on digital media. Control experiments
included incubation of slices in primary and secondary
antibody-free solutions both of which led to low intensity
non-specific staining patterns in preliminary experiments
(data not shown).
In vivo bromodeoxyuridine (BrdU) labeling and BrdU
immunohistochemistry
Labeling with BrdU was done to evaluate keratinocyte
proliferation. At 3 weeks after tibial fracture, animals
were injected intraperitoneally (i.p.) once daily with
50 mg/kg BrdU (Sigma-Aldrich) for 8 days [28]. Hindpaw
skin was harvested and fixed one day after the last injec-
tion and processed for immunostaining. Skin sections
were pretreated in 2 N HCl for 30 minutes at 37°C, fol-
lowed by neutralization in 0.1 M borate buffer (pH 8.5)
for 10 minutes and blocking with 10% normal donkey
serum for 1 h at room temperature, after which immuno-
histochemistry was performed using a rat anti-BrdU
monoclonal antibody (1:300, Accurate Chemical, WEST-
BURY, NY, USA) and donkey anti-rat fluorescein
isothiocyanate secondary antibody (1:400, Jackson
Immuno Research Laboratories). After three rinses with
PBS, the sections were immunostained with the mono-
clonal anti-rat keratin as mentioned above. BrdU im-
munostaining was observed using a Leica DM 2000
fluorescent microscope and imaged using a Spot Camera
(version 4.0.8, Diagnostic Instruments, Sterling Heights,
MI, USA). The number of BrdU-positive cells was
counted, specifically those in keratin-positive cells in the
area of the epidermis with a minimum of six sections
per animal from seven intact and five fractured animals.
Cell densities were calculated by dividing cell numbers
by the area. Representative images were obtained using
confocal microscopy (Zeiss LSM/510 Upright 2 photon;
Carl Zeiss).
Microcomputed tomography (μCT)
Ex vivo scanning was performed for assessment of tra-
becular and cortical bone architecture using micro com-
puter tomography (μCT) (VivaCT 40, Scanco Medical
AG, Basserdorf, Switzerland). Specifically, trabecular
bone architecture was evaluated at the distal femur and
cortical bone morphology was evaluated at the midshaft
femur. CT images were reconstructed in 1024 × 1024
pixel matrices for distal femur and mid-femur samples
and stored in 3-dimensional arrays. The resulting gray-
scale images were segmented using a constrained Gauss-
ian filter to remove noise, and a fixed threshold (25.5%
of the maximal grayscale value for the vertebrae and the
distal femur, and 35% for the mid-femoral cortical bone)
was used to extract the structure of the mineralized tis-
sue. The μCT parameters were set at threshold = 255,
σ= 0.8, support = 1 for vertebral samples, threshold =
255, σ= 0.8, support = 1 for distal femur, and threshold =
350, σ= 1.2, and support = 2 for mid-femur evaluation
analysis. A single operator outlined the trabecular bone
region within the distal femur, the vertebral body and
the cortical bone region in the mid-femoral shaft. The
trabecular bone region was manually identified and all
slices containing trabecular bone between the growth
plates were included for analysis. In the distal femur 150
transverse slices of 21 μm thickness (21-μm isotropic
voxel size) encompassing a length of 3.15 mm were ac-
quired, but only 100 slices encompassing 2.1 mm of the
distal femur were evaluated, starting where the growth
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plate bridge across the middle of the metaphysis ends.
The region of interest (ROI) was manually outlined on
each CT slice, extending proximally from the growth
plate. The bone parameters analyzed included the bone
volume fraction (BV/TV) (%), trabecular number (TbN)
(mm-1), trabecular thickness (TbTh) (μm), trabecular sep-
aration (TbSp) (μm), and connectivity density (ConnD)
(1/mm3). At the femoral mid-shaft, 10 transverse CTslices
were obtained, each 21 μm thick totaling 0.21 mm in
length (21 μm isotropic voxel size) and these were
used to compute the cortical bone area (Bar) (mm2),
total cross sectional area (TtAr) (mm2), medullary area
(MeAr) (mm2), cortical thickness (CtTh) (μm), bone per-
imeter (BPm) (mm), and relative cortical bone area
(BAr/TtAr) (%).
Study design
To determine the time course of SP-induced pain behav-
ior and signs of inflammation, normal rats received
hindpaw intraplantar injection of SP (0, 10, 25, and
60 μg) in 50 μl of 0.9% saline. Baseline determinations
were made of bilateral hindpaw mechanical nociceptive
withdrawal thresholds to von Frey fibers, hindpaw tem-
perature, and hindpaw thickness, and then the rats were
injected and retested for behavior at 0.5, 1, 3, 6, 24, 48,
and 72 h after SP injection (n = 6 per cohort). Based
on the results of this behavioral study, a 25 μg dose of
SP was selected for evaluating the time course of SP-
induced inflammatory mediator expression. After nor-
mal rats underwent intraplantar injection with 25 μg SP
in 50 μl of 0.9% saline, the hindpaw skin was collected at
0, 1, 3, 6, 24, and 48 h after injection for TNF-α, IL-1β,
IL-6, and NGF protein level determination by EIA (n = 8
per cohort).
The effects of SP (25 μg) intraplantar injection on
keratinocyte inflammatory mediator and NK1 receptor
expression were evaluated by immunofluorescence con-
focal microscopy. Normal rats received hindpaw intra-
plantar injections with 25 μg SP, and then the injected
hindpaw skin was collected at 0, 1, 3, and 6 h post-
injection for immunostaining with anti-IL-1β, NGF, or
NK1 primary antibody.
To evaluate the contribution of NGF signaling in
SP-evoked allodynia, the NGF inhibitor muMab 911
(10 mg/kg) or vehicle was administered via i.p. injection
in normal rats. Three days later, baseline hindpaw von
Frey thresholds, temperature, and paw thickness were
determined, and then the rats received an intraplantar
injection with 25 μg SP. At 0.5, 1, 3, 6, 24, 48, and 72 h
post-injection the animals underwent repeat tests.
To test the hypothesis that local SP signaling induces
hindpaw pain and inflammation in the CRPS tibial frac-
ture model, fracture rats were treated with either a sys-
temic or locally administered NK1 receptor antagonist
(LY303870). The rats were divided into four cohorts
(n = 8 to 16 rats per cohort). Three cohorts underwent
right distal tibial fracture with hindlimb cast immobi-
lization for 4 weeks. The day after cast removal, all rats
underwent bilateral hindpaw tests for von Frey thresh-
olds, unweighting, warmth, and edema. One fracture co-
hort had no treatment, one cohort received daily i.p.
injections of LY303870 (20 μg/kg) for 8 days prior to
cast removal, and one cohort received a single intraplan-
tar injection of LY303870 (50 μg/50 μl 0.9% saline) the
day after cast removal. At one hour after intraplantar in-
jection of LY303870 the rats were tested.
To evaluate the role SP signaling plays in post-fracture
keratinocyte proliferation in the injured limb, tibial
fracture rats were treated with vehicle or LY303870
(20 mg/kg i.p.) daily for 8 days prior to cast removal.
All rats were injected with BrdU (50 mg/kg i.p.) daily
for 8 days prior to cast removal. After cast removal
the hindpaw skin was harvested bilaterally for co-
immunostaining with anti-BrdU (DNA synthesis mar-
ker) and anti-keratin (keratinocyte marker) antibodies.
Confocal microscopy was used to measure the number
of BrdU-positive cells in the epidermis (n = 9 rats for
the control, ipsilateral fracture (FX-IPSI), and contra-
lateral fracture (FX-CONTRA) cohorts, and n= 4 for the
LY303870 treatment group), and to measure epidermal
thickness (n = 7 per cohort).
To test the hypothesis that SP signaling mediates
fracture-induced inflammatory mediator expression in
the hindpaw skin, three cohorts of rats were evaluated;
controls, vehicle-treated fractured rats, and LY303870-
treated fractured rats (n = 13 to 16 per cohort).
LY303870 (20 mg/kg) was given by i.p. injection daily
for 8 days prior to cast removal. After the casts were
removed at 4 weeks post-fracture the animals were eu-
thanized and the hindpaw skin collected for TNF-α,
IL-1β, IL-6, and NGF protein level determination by
EIA. The bilateral femurs were collected for ex vivo μCT
of the proximal metaphyseal trabecular and the mid-
femoral cortical bone to test the hypothesis that facilitated-
SP signaling contributes to periarticular bone loss after
fracture.
Statistical analysis
Statistical analysis was accomplished using a two-way
analysis of variance (ANOVA) followed by Bonferroni
post hoc tests for the time course of the SP injection at
various concentrations. One-way ANOVA was employed
followed by Neuman-Keuls multiple comparison test to
compare among the control, fractured and LY303870-
treated fractured rats. All data are presented as the
mean ± standard error (SE) of the mean, and differences
are considered significant at a P-value less than 0.05
(Prism 5, GraphPad Software, San Diego, CA, USA).
Wei et al. Journal of Neuroinflammation 2012, 9:181 Page 5 of 15
http://www.jneuroinflammation.com/content/9/1/181
Hindpaw temperature, thickness, and mechanical no-
ciceptive thresholds data were analyzed as the difference
between the treatment side and the contralateral un-
treated side. Right hindpaw weight bearing data were
analyzed as a ratio between the right hindpaw weight
and the sum of the right (R) and left (L) hindpaws values
((2R/(R + L)) × 100%).
Results
Time course and dosage for SP-induced allodynia,
warmth, and edema in the hindpaw
To determine the time course of SP-induced pain behav-
ior and signs of inflammation, normal rats received an
intraplantar SP (0, 10, 25, and 60 μg) injection, and then
hindpaw von Frey thresholds, temperature, and thick-
ness were determined at 0, 0.2, 1, 3, 6, 24, and 48 h
post-injection (Figure 1). Higher doses of SP (25 and
60 μg) caused von Frey allodynia that developed slowly,
peaking at 6 h and resolving by 48 h. SP injection had
no effect on hindpaw temperature, but did induce a
rapid onset of edema at all doses tested (10, 25 and
60 μg), that peaked at 1 h or 3 h and resolved by 24 h.
The discrepant time courses and doses required to in-
duce allodynia and edema suggest that different mechan-
isms mediate these peripheral effects of SP.
Time course for SP-induced TNF-α, IL-1β, and IL-6, and
NGF expression in hindpaw skin keratinocytes
To further elucidate the mechanisms responsible for SP-
induced pain behavior, TNF-α, IL-1β, IL-6, and NGF
protein levels in hindpaw skin were determined by EIA at
various time points after SP (25 μg) intraplantar injection
(Figure 2). TNF-α expression was upregulated at 1 h
Figure 1 Intraplantar injection of 10, 25, or 60 μg of substance P (SP) into the hindpaw of a normal rat dose-dependently induced
mechanical allodynia to von Frey testing. (A) Allodynia developed slowly, peaking at 6 h post-injection, and gradually resolving over 48 h. (B)
There were no changes in hindpaw temperature after injecting any dose of SP. (C) Even the lowest dose of SP (10 μg) evoked hindpaw edema
within 5 minutes, peaking at 1 h, and then gradually resolving over 24 h. Measurements for (A), (B), and (C) represent the difference between the
injected side and the contralateral paw; thus, a positive value represents an increase in temperature or paw thickness on the injected side, and a
negative value represents a decrease in mechanical nociceptive thresholds on the injected side. Data were analyzed to compare SP injection vs.
vehicle injection cohorts at various time points by two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test. *P< 0.05,
**P< 0.01 and ***P< 0.001, SP- vs. vehicle-injected rats at indicated time points (n = 6 for each injection group). (B) There was no significant
difference in hindpaw temperature between SP-injected and vehicle-injected rats at any time point. (C) Injection of SP at all concentrations (10,
25, and 60 μg) significantly evoked edema at all three time points of 1 h, 3 h and 6 h (***P< 0.001 SP- vs. vehicle-injected cohorts).
Figure 2 Cytokine TNF-α (A), IL-1β (B), IL-6 (C) and nerve
growth factor (NGF) (D) production in hindpaw skin was
measured by EIA assay at various time points after intraplantar
injection of 25 μg of substance P (SP). Assays were performed at
0, 1, 3, 6, 24, and 48 h. SP injection induced a significant increase in
all inflammatory mediators compared to baseline levels. TNF-α (A)
was elevated at just 1 h after injection (compared to controls), IL-1β
(B) and IL-6 (C) cytokine levels were elevated at 1 h and 3 h
post-injection, respectively, and NGF (D) levels gradually increased
over 24 h post-injection, dropping to baseline at 48 h. Data are
expressed as mean values (pg/mg protein) ± standard error (SE) (n = 8
per cohort) and analyzed using one-way analysis of variance (ANOVA)
followed by Neuman-Keuls multiple comparison test to compare
different time points. *P< 0.05, **P< 0.01 and ***P< 0.001 vs.
baseline at 0 h. #P< 0.05, ##P< 0.01 and ###P< 0.001 vs. peak values.
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post-injection, IL-6 and IL-1β levels were increased at
1 h and 3 h post-injection, respectively, and NGF expres-
sion gradually increased from 1 h to 24 h post-injection,
resolving by 48 h. Interestingly, the time course of post-
injection NGF upregulation most closely paralleled the
time course observed for SP-induced allodynia. When
the hindpaw skin was harvested at various time points
after SP (25 μg) injection for immunostaining with IL-1β
antibody, increased IL-1β protein was observed in
keratinocytes at 1 h and 3 h after SP injection, resolving
by 6 h, which corresponds to the time course observed
using EIA assays on skin homogenates (Figure 3). Simi-
larly, when hindpaw skin was immunostained for NGF,
increased levels of NGF were observed in the keratino-
cytes at 1, 3, and 6 h after SP injection (Figure 4). In
addition, an experiment was carried out to examine NK1
receptor expression after SP injection. Immunostaining
demonstrated increased NK1 receptor protein in the
Figure 3 Immunofluorescence confocal microscopy for keratin protein and IL-1β in the hindpaw skin after intraplantar injection of
substance P (SP). Kertain protein (a keratinocyte marker) (green), and IL-1β (red) are shown in control rats (top row of panels), and at 1 h
(second row), 3 h (third row), and 6 h (fourth row) after intraplantar injection of 25 μg SP. Increased IL-1β staining was observed in keratinocytes
at 1 h and 3 h after SP injection, resolving by 6 h, which corresponds to the time course observed using EIA assays in hindpaw skin
homogenates (Figure 2). Scale bar = 20 μm.
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keratinocytes at 1 h and 3 h after SP injection, resolving
by 6 h (Figure 5).
Effects of anti-NGF antibody on SP-evoked nociceptive
and vascular abnormalities
The effects of anti-NGF treatment on SP-evoked hind-
paw mechanical sensitivity, warmth, and edema were
monitored for 72 h. Figure 6 illustrates that von Frey
nociceptive thresholds in the right hindpaw were re-
duced after SP (25 μg) intraplantar injection but anti-
NGF antibody treatment (muMab 911, 10 mg/kg i.p.,
given 3 days prior to testing) completely blocked the
development of this mechanical allodynia. Anti-NGF
antibody had no effect on hindpaw temperature or on
SP-evoked hindpaw edema.
Effects of systemic or localized LY303870 treatment on
fracture-induced nociceptive and vascular abnormalities
These experiments tested the hypothesis that SP signal-
ing in the hindpaw skin is responsible for fracture-induced
Figure 4 Co-immunostaining for keratin protein and nerve growth factor (NGF) in the hindpaw skin after intraplantar injection of
substance P (SP). Keratin protein (green) and NGF (red) are shown in control rats (top row of panels), and at 1 h (second row), 3 h (third row),
and 6 h (fourth row) after intraplantar injection of 25 μg SP. Increased NGF staining was observed in keratinocytes at 1, 3 and 6 h after SP
injection, corresponding to the prolonged allodynia observed after SP injection (Figure 1). Scale bar = 40 μm.
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nociceptive and vascular changes. Rats underwent tibial
fracture and cast immobilization for 4 weeks, then the
cast was removed and on the following day the rats were
tested for hindpaw allodynia, unweighting, warmth and
edema. Fracture reduced von Frey nociceptive thresholds
in the fractured hindpaw from 0.88 to −8.97 g (Figure 7).
Untreated fracture rats unweighted the ipsilateral hindpaw
by 43%. Fracture also increased hindpaw skin temperature
by 5.2°C and thickness by 1.7 mm. When the NK1
receptor antagonist LY303870 (20 mg/kg/day) was
injected i.p. for 8 consecutive days prior to cast removal
there was a reduction in hindpaw allodynia, unweighting,
warmth, and edema by 83, 80, 64, and 67%, respectively.
Similarly, a single intraplantar injection of LY303870
(50 μg/50 μl saline) into the hindpaw skin of the frac-
tured limb 1 h prior to behavioral testing also reduced
hindpaw allodynia and unweighting, but had no effect
on temperature or edema. These results suggest that
Figure 5 Labeling for keratin protein and the NK1 receptor (NK1R) in the hindpaw skin after intraplantar injection of substance P (SP).
Keratin protein (red) and NK1R (green) are shown in control rats (top row of panels), and at 1 h (second row), 3 h (third row), and 6 h (fourth
row) after intraplantar injection of 25 μg SP. Increased NK1R staining was observed in keratinocytes at 1 h and 3 h after SP injection, resolving by
6 h post-injection. These results suggest that facilitated SP signaling is not responsible for the prolonged hyperalgesia observed after SP injection
(Figure 1). Scale bar = 20 μm.
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SP signaling in the hindpaw skin contributes to the
maintenance of pain behavior in the injured limb at
4 weeks post-fracture. We suspect that the discrepancy
between the effects of systemic and intraplantar
LY303870 in reversing post-fracture hindpaw warmth
and edema reflect the brief duration of the intraplantar
LY303870 injection effect. The very low dose (50 μg,
or approximately 0.1 mg/kg) of LY303870 used in the
intraplantar injection experiment had no behavioral
effects when given systemically, and the analgesic effects
observed after intraplantar LY303870 injection resolved
by 2 h post-injection (data not shown), suggesting that the
drug had dispersed systemically within 2 h post-injection
and was no longer reaching effective concentrations in the
hindpaw skin.
Effects of LY303870 on fracture-induced hindpaw
keratinocyte proliferation and epidermal hyperplasia
We previously observed that distal tibial fracture led to
chronic keratinocyte proliferation and epidermal hyperpla-
sia in the hindpaw skin [8] and we hypothesized that SP-
signaling was responsible for fracture-induced hindpaw
keratinocyte proliferation. To test this hypothesis, BrdU
Figure 6 This experiment tested the hypothesis that the delayed onset, long lasting allodynia evoked by intraplantar injection of
substance P (SP) was mediated by increased nerve growth factor (NGF) expression in skin keratinocytes. Rats (n = 8 per cohort) were
treated with either anti-NGF antibody (10 mg/kg i.p. muMab 911) or vehicle, 3 days prior to undergoing intraplantar SP (25 μg) injection. (A) SP
injection induced a slowly developing von Frey allodynia that peaked at 6 h post-injection, but SP-induced allodynia was blocked by
pretreatment with anti-NGF. (B) There were no changes in hindpaw temperature after injecting SP. (C) Anti-NGF pretreatment had no effect on
SP-evoked hindpaw edema. Measurements for (A), (B), and (C) represent the difference between the injected side and the contralateral paw, thus
a positive value represents an increase in temperature or paw thickness on the injected side; a negative value represents a decrease in
mechanical nociceptive thresholds on the injected side. Behavioral data after SP injection were analyzed by two-way analysis of variance (ANOVA)
followed by Bonferroni post hoc test to compare differences between rats pretreated with and without anti-NGF antibody at indicated time
points. *P< 0.05 and **P< 0.01 vehicle vs. anti-NGF antibody pretreatments.
Figure 7 Three cohorts of rats underwent right distal tibial fracture and hindlimb cast immobilization for four weeks. After baseline
testing, rats were divided into 4 groups. One fracture (FX) group had no other treatment (FX, n = 16), another fracture group underwent daily
intraperitoneal (i.p.) injections with the NK1 receptor antagonist LY303870 (20 mg/kg i.p., FX + LY303870 i.p., n = 15) over an 8-day interval prior to
cast removal, and another fracture group underwent a single intraplantar (i.p.l) injection of LY303870 (50 μg) on the day after cast removal and
1 h prior to testing (FX + LY303870 i.p.l. 1 h, n = 8). At four weeks post-fracture the 8 days of systemic LY303870 treatment reduced hindpaw
mechanical allodynia (A), unweighting (B), warmth (C) and edema (D) that developed after fracture. In addition, all four tests were carried out 1 h
after the intraplantar injection of LY303870. A single intraplantar injection of LY303870 also reduced allodynia and unweighting, but had no effect
on warmth or edema. Measurements for (A), (C), and (D) represent the difference between the fracture side and the contralateral paw, thus a
positive value represents an increase in temperature or thickness on the fracture side; a negative value represents a decrease in mechanical
nociceptive thresholds on the affected side. Measurements for (B) represent weight-bearing on the fracture hindlimb as a ratio to 50% of bilateral
hindlimb loading, thus a percentage lower than 100% represents hindpaw unweighting. Data were analyzed using one-way analysis of variance
(ANOVA) followed by Neuman-Keuls multiple comparison test. *P< 0.05, **P< 0.01, ***P< 0.001 fracture vs. control (n = 13) values, and ##P< 0.01
and ###P< 0.001 for fracture with LY303870 treatments vs. fracture with vehicle treatment.
Wei et al. Journal of Neuroinflammation 2012, 9:181 Page 10 of 15
http://www.jneuroinflammation.com/content/9/1/181
was used to label DNA synthesis in proliferating keratino-
cytes. Figure 8 shows representative confocal images of
BrdU (green) and keratin (a keratinocyte marker, red) in
hindpaw skin sections from control rats, from the ipsilat-
eral hindpaw of 4-week post-fracture rats, and from the ip-
silateral hindpaw of 4 week post-fracture rats treated with
LY303870 (20 mg/kg/day for 8 days just prior to cast re-
moval). Only a few BrdU-positive cells were detected in
control skin (Figure 8A, upper row of panels), but skin
sections from fracture rats demonstrated a large number
of BrdU-positive cells in the epidermis co-labeled for kera-
tin, including the basal layer where new keratinocytes are
generated (Figure 8A,middle row of panels). Interestingly,
LY303870 treatment blocked the fracture-induced in-
crease in BrdU-positive cell numbers in the epidermis
(Figure 8A, bottom row of panels). Quantitation of the
BrdU-positive cells in hindpaw skin revealed a 2.3 fold in-
crease in BrdU-positive cells in the fractured limb (FX-
IPSI) compared to the control (Figure 8B). No increase in
BrdU-positive cells was observed in the hindpaw contralat-
eral to the fractured limb (FX-CONTRA). Furthermore,
LY303870 treatment reversed the fracture-evoked increase
of BrdU-positive cell number in the epidermis (Figure 8B).
To evaluate epidermal thickening after fracture, hindpaw
skin sections were stained for keratin (green) (Figure 9).
Consistent with the BrdU results, we observed that frac-
ture increased epidermal thickness and that the treat-
ment with LY303870 for 8 days prior to cast removal
blocked epidermal thickening. These results support the
hypothesis that SP signaling is responsible for fracture-
induced keratinocyte proliferation and epidermal hyper-
plasia in the hindpaw skin.
Effects of LY303870 on fracture-induced TNF-α, IL-1β, IL-6,
and NGF expression in hindpaw skin
To elucidate the involvement of SP signaling in fracture-
induced upregulation of TNF-α, IL-1β, IL-6, and NGF,
fractured rats were injected with LY303870 (20 mg/kg/
day, i.p.) or vehicle for 8 consecutive days prior to behav-
ioral testing and skin harvesting at 4 weeks post-fracture.
Cytokines and NGF were determined by EIA of hindpaw
skin homogenates. Figure 10 illustrates that TNF-α, IL-1β,
IL-6 and NGF protein levels in the hindpaw skin were
increased by 1593, 176, 33.9, and 495%, respectively, at
4 weeks after tibial fracture. LY303870 treatment reversed
the fracture-induced upregulation of these proinflammatory
cytokines and NGF, by 69.9, 105.9, 171.6, and 91.5%, re-
spectively, indicating that SP signaling plays a critical role in
post-fracture inflammatory mediator expression.
Figure 8 Co-immunostaining for keratin and bromo-2-deoxyuridine (BrdU) in the hindpaw skin four weeks post-fracture. (A) Top panels
are images from a normal control rat, middle panels are from a fracture rat, and lower panels are from a fracture rat treated with an NK1 receptor
antagonist (LY303870 20 mg/kg, i.p. daily for 8 days), showing keratin staining (red) and BrdU (a marker of DNA synthesis) staining (green).
Fracture increased BrdU staining in keratinocytes, indicating increased cellular proliferation, and LY303870 treatment prevented this increase. Scale
bar = 50 μm. (B) There was a 3.3 fold increase in BrdU-positive cell numbers at 4 weeks post-fracture in the ipsilateral fracture paw (FX-IPSI), but
not in the contralateral paw (FX-CONTRA), and this increase was blocked in fractured rats treated with LY303870 (FX+ LY303870). Data were
analyzed using one-way analysis of variance (ANOVA) followed by Neuman-Keuls multiple comparison test. ***P< 0.001 for FX-IPSI (n = 9) vs.
control (n = 9), and ###P< 0.001 for FX + LY303870 (n = 4) and FX-CONTRA (n = 9) vs. FX-IPSI cohorts.
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Effects of LY303870 on fracture-induced bone loss
At 4 weeks post-fracture there was significant reduction
in trabecular % BV/TV in the distal femur ipsilateral,
but not contralateral to the tibial fracture (n = 10 per co-
hort) (Table 1). Distal femoral TbTh and ConnD were
also reduced after fracture. No changes were observed in
% BAr/TtAr after fracture. Treatment with the NK1 re-
ceptor antagonist LY303870 (20 mg/kg/day i.p. for 8 days
just prior to cast removal) had no effect on bone loss in
the distal femur, suggesting that SP signaling through
the NK1 receptor does not contribute to the periarticu-
lar trabecular bone loss observed after tibial fracture.
Discussion
Substantial evidence exists to suggest that neuropeptide
mediated mechanisms support pain and edema in CRPS.
Using a rat model involving tibial fracture and cast im-
mobilization that faithfully reproduces many of the fea-
tures of CRPS type I in humans, we previously showed
that SP signaling through the NK1 receptor was required
for the full manifestation of the syndrome [2]. Similar
findings were reported using a sciatic section model of
CRPS type II, a condition defined as involving frank dam-
age to a peripheral nerve [27]. Unknown, however, is the
mechanism through which SP acts to cause the CRPS-
related changes. Additional data suggest that cytokines
such as TNF-α, IL-1β, and IL-6, as well as the neurotro-
phin NGF, might contribute to pain and vascular changes
in CRPS [4,5,7,8]. Therefore, we set out to determine if
SP-supported production of any of these mediators con-
tributes to the CRPS phenotype in the rat fracture/cast
model. We found that 1) the time course of NGF produc-
tion after intradermalCRPS injectionmost closelymatched
the time course of SP-mediated nociceptive sensitization; 2)
SP-stimulated NGF production was localized to the epi-
dermal keratinocytes; 3) anti-NGF could completely block
the nociceptive changes but not the vascular effects of
SP; 4) the blockade of SP signaling using the NK1 recep-
tor antagonist LY303870 effectively reduced nociceptive
and vascular manifestations of CRPS in the fracture/cast
model, but not bone-related changes; 5) the keratinocyte
proliferation characteristic of CRPS in the rat model was
dependent on SP signaling, and 6) LY303870 blocked the
Figure 9 Immunostaining for keratin in the hindpaw skin four
weeks post-fracture. Panels exhibit confocal images from the
hindpaw skin of a normal control rat, the ipsilateral hindpaw skin of
a fracture rat (FX-IPSI), the contralateral hindpaw skin of a fracture rat
(FX-CONTRA), and the ipsilateral hindpaw skin of a fracture rat
treated with an NK1 receptor antagonist (LY303870 20 mg/kg, i.p.
daily for 8 days, FX + LY-IPSI), showing staining for keratin (green).
Scale bar = 25 μm. There was an increase in epidermal thickness,
indicating increased keratinocyte proliferation, at 4 weeks post-
fracture in the fracture paw (FX-IPSI), but not in the contralateral
paw (FX-CONTRA), and this increase was blocked in fractured rats
treated with LY303870 (FX + LY-IPSI).
Figure 10 Cytokine TNF-α (A), IL-1β (B), IL-6 (C) and nerve growth factor (NGF) (D) levels in hindpaw skin were measured by EIA assay
at four weeks post-fracture. Rats were treated with vehicle (FX, n = 16) or the NK1 receptor antagonist LY303870 (20 mg/kg i.p. daily for 8 days
just prior to cast removal, FX + LY303870, n = 15). Fracture induced an increase in all inflammatory mediators compared to controls and this was
blocked in the LY303870-treated fractured rats. Data are expressed as mean values (pg/mg protein) ± standard error (SE). Data were analyzed
using one-way analysis of variance (ANOVA) followed by Neuman-Keuls multiple comparison test. *P< 0.05 and ***P< 0.001 vs. untreated
controls (n = 13), ##P< 0.01 and ###P< 0.001 for FX + LY303870 vs. fracture.
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production of NGF as well as several cytokines in the
skin of the fracture/cast rats. Together these results in-
dicate that while SP has many effects related to the mani-
festations of CRPS, it is the stimulation of NGF
production that seems to be most closely related to sup-
porting nociceptive sensitization.
Neuropeptides, most notably SP, have been implicated
in the pathophysiology of CRPS in both humans and,
correspondingly, in animal models. Analysis of venous
blood showed elevation of SP in CRPS patients [29].
When SP was administered to CRPS skin through mi-
crodialysis fibers, enhanced levels of protein extravasa-
tion were seen relative to the responses in unaffected
individuals [11]. Furthermore, electrical stimulation of
the limbs of patients with CRPS leads to greater
neuropeptide-dependent protein extravasation than in
control individuals [9]. It is notable that the use of an-
giotensin converting enzyme inhibitors leads to an ap-
parent increased risk for the development of CRPS
[30]. These agents slow the breakdown of SP.
Previously reported animal studies support these
observations. For example, animals deficient in the endo-
genous SP-metabolizing enzyme, neutral endopeptidase
(NEP), develop greater nociceptive and limb neurogenic
changes after chronic constriction injury (CCI) [31]. As
mentioned above, previous experiments from our own
laboratory demonstrated that NK1 antagonism inhibited
nociceptive sensitization in models of both CRPS I and II
[2,27]. It may also be relevant that SP-deficient mice have
less robust allodynia and cytokine generation in skin after
hindpaw incision [32], and that NK1 receptor antagonists
have been demonstrated to be effective analgesics for
post-operative pain in a clinical trial [33] (though not in
trials involving other types of pain). While no clinical
trial data are currently available examining NK1 receptor
antagonist efficacy in CRPS, future trials might have their
greatest opportunity for success in patients with acute or
warm-phase CRPS syndrome where neurogenic inflam-
mation is most prominent. This is the time period most
similar to the rodent model used in these studies.
Our studies went beyond the simple description of
NK1 control of specific cytokines and NGF in paw skin
after SP administration and in the fracture model of
CRPS. We attempted to determine which of the several
mediators was most closely linked to SP’s pro-nociceptive
effects. Based on the time course of production and the
time course for nociceptive sensitization, NGF appeared
to be the most plausible candidate. In fact, anti-NGF was
able to block the pro-nociceptive effects of SP, but not
the vascular effects, which follow a distinctly shorter time
course. Earlier studies demonstrated that the same anti-
NGF reagent blocked nociceptive sensitization but not
the production of other inflammatory mediators in the
fracture model [5]. The NK1 receptor antagonist also
blocked NGF production in the fracture model. Further-
more, the current study demonstrated that epidermal
keratinocytes are the cellular source for cutaneous NGF
after SP injection. Both rodents and humans express
NK1 receptors on keratinocytes [14,34]. It seems reason-
able to hypothesize that NGF formed in the epidermis
stimulates TrkA, expressing primary afferent neurons
leading to nociceptive sensitization [35]. NGF receptors
on vascular tissue are far less well described. Though
data from human trials conducted on CRPS patients are










BV/TV (%) 12.5 ± 0.6 6.60 ± 1.22*** 7.31 ± 0.72*** 10.63 ± 1.27 11.13 ± 0.84*
TbN (mm-1) 2.78 ± 0.08 2.38 ± 0.17 2.43 ± 0.14 2.91 ± 0.17 2.87 ± 0.15
TbTh (μm) 65.3 ± 1.1 57.6 ± 2.2*** 62.1 ± 1.2*** 63.2 ± 2.2 66.5 ± 1.2
TbSp (μm) 372± 11 441 ± 31 428 ± 25 358 ± 22 360± 18
ConnD (1/mm3) 40.0 ± 2.7 14.0 ± 4.3*** 14.7 ± 2.5** 29.5 ± 5.2* 29.4 ± 3.8*
Femur midshaft
BAr (mm2) 7.36 ± 0.13 7.42 ± 0.13 7.34 ± 0.21 7.27 ± 0.14 7.34 ± 0.20
TtAr (mm2) 13.4 ± 0.4 13.4 ± 0.3 13.1 ± 0.3 13.2 ± 0.3 13.1 ± 0.3
MeAr (mm2) 6.11 ± 0.29 5.99 ± 0.22 5.74 ± 0.24 5.96 ± 0.21 5.72 ± 0.23
CtTh (μm) 703± 6 720 ± 7 723 ± 18 707 ± 8 725± 20
BPm (mm) 23.9 ± 0.5 22.4 ± 0.4* 21.3 ± 0.4** 22.6 ± 0.4 21.9 ± 0.3**
BAr/TtAr (%) 54.8 ± 0.9 55.4 ± 0.7 56.2 ± 1.3 55.0 ± 0.5 56.2 ± 1.3
Statistical significance determined from one-way analysis of variance (ANOVA) followed by post hoc Newman-Keuls test. All data are expressed as
means ± standard error of the mean. *P< 0.05, **P< 0.01 and ***P< 0.001 vs. controls.
BV: bone volume; TV: total volume; TbN: trabecular number; TbTh: trabecular thickness; TbSp: trabecular separation; ConnD: connectivity density; Bar: bone area:
TtAr: total cross sectional area; MeAr: medullary area; CtTh: cortical thickness; BPm: bone perimeter; LY: LY303870.
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not available, anti-NGF has the ability to reduce other
forms of refractory chronic pain in humans including
back pain and pain due to osteoarthritis [36-39]. Our
data suggest that anti-NGF might be an effective therapy
for the pain, but not the vascular changes associated with
CRPS.
Skin is the body’s largest organ, and keratinocytes are
the most common cell type in the epidermis, the skin’s
outermost cellular layer. Far from performing only the
function of providing a barrier against external threats,
skin has a number of endocrinologic and immunologic
roles. Indeed the skin has various roles in supporting
pain. Recent studies of gene expression and keratinocyte
function suggest that functional changes in these cells
support pain in several clinical pain syndromes. For ex-
ample, studies of skin biopsies from patients with both
post-herpetic neuralgia and CRPS I have identified
alterations in several sodium ion channel types including
Na(v) 1.2, 1.2, 1.5, 1.6, 1.7 and 1.8, channels normally
associated with controlling the electrical excitability of
nociceptive neurons [40]. While the function of those
channels in keratinocytes is somewhat unclear, recent
observations describe a more plausible mechanism sup-
porting nociception involving the expression of CGRP.
The skin of patients with painful neuropathies was ob-
served to produce the β form of CGRP aberrantly [41].
Keratinocyte release of this neuropeptide would allow it
to interact with nociceptive nerve terminals in the epi-
dermis and to act in a paracrine and autocrine fashion
on other keratinocytes, providing potential mechanisms
for skin to enhance nociceptive sensitivity. Likewise we
have identified cytokines such as IL-1β, IL-6, TNF-α as
well as NGF in the keratinocytes of mice and rats after
tibial fracture and immobilization [8]. Significantly, per-
ipherally restricted biologic antagonists to these media-
tors are very effective in reducing the nociceptive and
related changes characteristic of CRPS I in rats [4,5,7].
In the present set of studies we were able to refine our
understanding of the neuroinflammatory link between
SP and NGF production at the cellular level in a fracture
model of CRPS. Not only were NK1 receptors upregu-
lated on keratinocytes after SP injection, but NGF pro-
duction was strongly enhanced as well. Finally, we
observed that SP affected more than just mediator pro-
duction in keratinocytes, in that cellular proliferation
was stimulated as well. Trophic changes involving the
skin are characteristic of many patients with CRPS. Thus
keratinocytes are affected in multiple ways by the release
of SP.
A range of SP effects have been observed in models of
acute and chronic pain. Signaling mediated by this mol-
ecule has been studied in translational fashion in some
detail. While there have been disappointments in drug
development efforts where blockade of SP signaling was
hoped to have immediate analgesic benefits in otherwise
normal patients [42], SP is still likely to support more
complex biological pathways. It has been shown to be
highly active in human skin, especially in the setting of
CRPS. Our results suggest that we should focus more on
SP’s ability to support the production of additional down-
stream mediators, like NGF, in indirectly supporting
nociceptive sensitization. We also need to realize that
changes in the skin of patients with CRPS are complex,
and that there may be no single signaling pathway ad-
equately explaining all relevant changes. Thus the princi-
pal goal to be set for future investigations in this area
might be to integrate the functions of the already identi-
fied signaling molecules, systems and cascades into a co-
herent representation of the pathophysiology of CRPS.
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